Trial Profile
Single Arm, Neoadjuvant, Phase II Trial of Pertuzumab and Trastuzumab Administered Concomitantly With Weekly Paclitaxel and FEC for Clinical Stage I-II HER2-Positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- 18 Mar 2020 Status changed from active, no longer recruiting to completed.
- 10 Jan 2018 Planned End Date changed from 1 Jun 2017 to 1 Dec 2018.
- 10 Jan 2018 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2018.